Cat. No.: HY-107377

Copy Link Print Information

Benzo[a]pyrene

(Synonyms: 3,4-Benzopyrene)

10 Cited Publications

Customer Review

Based on 10 publication(s) in Google Scholar

Benzo[a]pyrene shows lung carcinogenicity in animal models, and it is frequently used in chemoprevention studies.

For research use only. We do not sell to patients.

Purity: 99.98%
CAS No.: 50-32-8
Formula: C₂₀H₁₂
Molecular Weight:252.31

Storage:

Store at room temperature 3 years.

In solvent -80°C, 2 years , -20°C, 1 year

Benzo[a]pyrene Chemical Structure

CAS No.: 50-32-8

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- Induced Disease Models
Chemical Information
Publications (10)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Benzo[a]pyrene shows lung carcinogenicity in animal models, and it is frequently used in chemoprevention studies.

All Endogenous Metabolite Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
MCF7	EC₅₀	2.7 μM Compound: 2	Agonist activity at aryl hydrocarbon receptor in human MCF7 cells after 24 hrs CYP1A1-dependent EROD assay Agonist activity at aryl hydrocarbon receptor in human MCF7 cells after 24 hrs CYP1A1-dependent EROD assay	[PMID: 20060304]

Induced Disease Models

Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

Benzo[a]pyrene (B[a]P) can be used to create lung tumor models. The bioavailability of Benzo[a]pyrene in rats is 10%, with a half-life of 16.6 hours. In female A/J mice, compared to the vehicle group, the 1.0 mg Benzo[a]pyrene treatment group shows statistically significant differences at 7 weeks, indicating that Benzo[a]pyrene-induced lung tumorigenesis is dose-dependent. The incidence of hyperplasia in female mice treated with 0.25, 0.50, and 1.0 mg Benzo[a]pyrene is significantly higher than in the vehicle group, and the adenoma incidence in the 1.0 mg Benzo[a]pyrene group is also significantly increased. Additionally, the multiplicity of hyperplasia in the 0.50 or 1.0 mg Benzo[a]pyrene treatment groups and the multiplicity of adenomas in the 1.0 mg group are significantly higher than in the vehicle group. Benzo[a]pyrene significantly increases the incidence of hyperplasia and adenomas in female A/J mice in a dose-dependent manner. On average, Benzo[a]pyrene induces the formation of 9.38±1.75 tumors, with an average tumor burden of 19.53±3.81 mm³. Administration of Benzo[a]pyrene also significantly decreases the levels of cAMP in the tumor and surrounding lung tissue and increases the expression levels of the PDE4D gene^[1]^[2].

Induction of Lung cancer^[4]^[5]

Background

Benzo[a]pyrene can covalently bind to DNA to form DNA adducts, which can lead to DNA damage and mutation. These conjugations can interfere with DNA replication and repair processes, causing genetic mutations and chromosomal abnormalities that lead to tumor formation.

Specific Modeling Methods

Mice: Swiss albino mice • 8-10 weeks old • male
Administration: 50 mg/kg• p.o. • twice a week (1st and 4th day) for four successive weeks

Note

(1) Benzo[a]pyrene was dissolved in olive oil.
(2) All procedures were performed at temperatures ranging between 0 and 4°C.
(3) At the end of the experimental period, the animals were sacrificed. Lung tissues were isolated, washed in ice cold 1.15 % KCl and homogenized.

Modeling Indicators

Molecular changes:The contents of TNF-α, IL-6, COX-2 and NF-ΚB were detected.
Histological analysis:Toluidine blue staining was used to detect the number of mast cells.

Correlated Product(s): Capsaicin (HY-10448)

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 50-32-8
Appearance Solid
Molecular Weight 252.31
Formula C₂₀H₁₂
Color Light yellow to yellow
SMILES

C12=C(C=C3)C=C(C=CC=C4)C4=C1C=CC5=CC=CC3=C25
Synonyms

3,4-Benzopyrene
Structure Classification
- Others
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Store at room temperature 3 years

In solvent	-80°C	2 years
	-20°C	1 year

Publications (10)

All In Vivo Efficacy StudyCell Imaging/StainingWBELISA

Sort by:

Journal Impact Factor

Allergy

Identification of Key Genes Associated With Epithelial Barrier Dysfunction by Comprehensive Analysis and Experimental Validation. [Abstract]

2026 Feb 27. PMID: 41755794
Environ Pollut

Machine learning and multi-dimensional transcriptomics reveal the key molecular network of benzo(a)pyrene/NNK in promoting laryngeal cancer and develop prognostic models. [Abstract]

2026 Jul 15:401:128275. PMID: 42107864
Cancer Cell Int

USP29 activation mediated by FUBP1 promotes AURKB stability and oncogenic functions in gastric cancer. [Abstract]

2024 Jan 17;24(1):33. PMID: 38233848

Benzo[a]pyrene purchased from MedChemExpress. Usage Cited in: Cancer Cell Int. 2024 Jan 17;24(1):33. [Abstract]

Representative images showed gross morphology of stomachs harboring Benzo[a]pyrene (BaP)-induced tumors (50 mg/kg; i.g.; twice a week for 6 weeks) from wildtype and Usp29^−/− mice.
Ecotoxicol Environ Saf

Benzo[a]pyrene exacerbates bone destruction by inhibiting Treg differentiation, impairing Treg function and promoting osteoclastogenesis in rats with collagen-induced arthritis. [Abstract]

2026 May:316:120135. PMID: 41980281
Ecotoxicol Environ Saf

Integrating network toxicology and experimental validation to elucidate the molecular mechanism basis of chondrotoxicity of Benzo[a]pyrene in osteoarthritis. [Abstract]

2026 May:316:120177. PMID: 42034589
Int Immunopharmacol

TNFAIP3, PADI4, and CXCR4 as biomarkers of neutrophil extracellular traps in severe asthma. [Abstract]

2025 Dec 29:170:116118. PMID: 41475137

Benzo[a]pyrene purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2025 Dec 29:170:116118. [Abstract]

SYTOX Green staining to visualize NETs formation in neutrophils after Benzo[a]pyrene (BaP) (10 μM; 24 h) exposure.

Benzo[a]pyrene purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2025 Dec 29:170:116118. [Abstract]

Western blot analysis detecting H3Cit levels in neutrophils treated with different Benzo[a]pyrene (BaP) (5-10 μM; 24 h) concentrations. Benzo[a]pyrene (BaP) increased NETs generation in a dose-dependent manner.

Benzo[a]pyrene purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2025 Dec 29:170:116118. [Abstract]

The levels of MPO-DNA complexes in the neutrophil culture supernatants were measured following transfection with siRNAs targeting PADI4. Benzo[a]pyrene (BaP) (100 μg/mL; 24 h) markedly promoted NETs formation in HL60-induced neutrophil models.
Mol Divers

Multi-omics, molecular modeling and experimental analysis of carcinogen benzo(a)pyrene promoting the progression of laryngeal cancer. [Abstract]

2026 Apr 19. PMID: 42001354
Neurotoxicology

The use of tocofersolan as a rescue agent in larval zebrafish exposed to benzo[a]pyrene in early development. [Abstract]

2021 Sep:86:78-84. PMID: 34273383

Benzo[a]pyrene purchased from MedChemExpress. Usage Cited in: Neurotoxicology. 2021 Sep:86:78-84. [Abstract]

Under all lighting conditions, Benzo[a]pyrene (BaP) (5 μM; from 5 hpf until 5 dpf) significantly reduced the activity level of zebrafish compared to the control group.
Vascul Pharmacol

Benzo[a]pyrene exacerbates atherosclerosis by upregulating SPP1 to promote macrophage inflammation and lipid dysregulation: An integrated network toxicology, RNA-seq, and experimental validation study. [Abstract]

2026 Mar:162:107589. PMID: 41747816
Research Square Preprint

2022 Feb.

Solvent & Solubility

In Vitro:

DMSO : 16.67 mg/mL (66.07 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.9634 mL

19.8169 mL

39.6338 mL

5 mM

0.7927 mL

3.9634 mL

7.9268 mL

10 mM

0.3963 mL

1.9817 mL

3.9634 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.67 mg/mL (6.62 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 1.67 mg/mL (6.62 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 1.67 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.67 mg/mL (6.62 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 1% CMC-Na/saline water

Solubility: 5 mg/mL (19.82 mM); Suspended solution; Need ultrasonic and warming and heat to 50°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Animal Administration^[2]

Female A/J mice are randomized into eight groups (n=8): (i) control; (ii)Benzo[a]pyrene (B(a)P)+vehicle (methocel); (iii) Benzo[a]pyrene+roflumilast 1 mg/kg; (iv) Benzo[a]pyrene+roflumilast 5 mg/kg; (v) Benzo[a]pyrene+aerozolie phosphate-buffer saline (PBS); (vi) Benzo[a]pyrene+aerosolize budesonide 2.25 mg/mL; (vii) Benzo[a]pyrene+aerosolized budesonide 2.25 mg/mL+roflumilast 1 mg/kg; and (viii) Benzo[a]pyrene+aerosolize budesonide 2.25 mg/mL+roflumilast 5 mg/kg groups. A single dose of Benzo[a]pyrene in corn oil is given intraperitoneally once at 100 mg/kg body weight. Roflumilast (1 or 5 mg/kg) is started 2 weeks after Benzo[a]pyrene. It is continued for 26 weeks (3 days/week) via oral gavage. Mice in the Benzo[a]pyrene+vehicle group are treated with an equal volume of methocel as solvent control. Aerosolizing budesonide is administrated by inhaling route as an aerosol at a dose of 2.25 mg/mL for 2 min per application at 2 weeks after Benzo[a]pyrene. It is continued for 26 weeks (5 days/week). PBS is also used as solvent control by inhaling route after Benzo[a]pyrene administration in the Benzo[a]pyrene+PBS group. Mice are killed at 28 weeks after exposure to Benzo[a]pyrene. Their lungs are excised and stored at -70 °C^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (761 KB)
- English - EN (761 KB)
- Français - FR (761 KB)
- Deutsch - DE (761 KB)
- Norwegian - NO (761 KB)
- Español - ES (761 KB)
- Swedish - SV (761 KB)
- Italian - IT (761 KB)
- Korean - KR (761 KB)
- Portuguese - PT (761 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Saeko Onami, et al. Dosimetry for lung tumorigenesis induced by urethane, 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK), and benzo[a]pyrene (B[a]P) in A/JJmsSlc mice. J Toxicol Pathol. 2017 Jul; 30(3): 209–216. [Content Brief]

[2]. Yeo CD, et al. Roflumilast treatment inhibits lung carcinogenesis in benzo(a)pyrene-induced murine lung cancer model. Eur J Pharmacol. 2017 Oct 5;812:189- [Content Brief]

[3]. Foth H, et al. Pharmacokinetics of low doses of benzo [a] pyrene in the rat[J]. Food and chemical toxicology, 1988, 26(1): 45-51.

[4]. Anandakumar P, et al. Capsaicin inhibits benzo(a)pyrene-induced lung carcinogenesis in an in vivo mouse model. Inflamm Res. 2012 Nov;61(11):1169-75. [Content Brief]

[5]. Kasala ER, et al. Benzo(a)pyrene induced lung cancer: Role of dietary phytochemicals in chemoprevention. Pharmacol Rep. 2015 Oct;67(5):996-1009. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.9634 mL	19.8169 mL	39.6338 mL	99.0845 mL
	5 mM	0.7927 mL	3.9634 mL	7.9268 mL	19.8169 mL
	10 mM	0.3963 mL	1.9817 mL	3.9634 mL	9.9084 mL
	15 mM	0.2642 mL	1.3211 mL	2.6423 mL	6.6056 mL
	20 mM	0.1982 mL	0.9908 mL	1.9817 mL	4.9542 mL
	25 mM	0.1585 mL	0.7927 mL	1.5854 mL	3.9634 mL
	30 mM	0.1321 mL	0.6606 mL	1.3211 mL	3.3028 mL
	40 mM	0.0991 mL	0.4954 mL	0.9908 mL	2.4771 mL
	50 mM	0.0793 mL	0.3963 mL	0.7927 mL	1.9817 mL
	60 mM	0.0661 mL	0.3303 mL	0.6606 mL	1.6514 mL

Keywords

Benzo[a]pyrene

10 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Benzo[a]pyrene

Metabolism/Protease Compound Library

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Lung Cancer Compound Library

Tumorigenesis-Related Compound Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Mitochondrial Toxicity Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Tibetan Medicine Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Benzo[a]pyrene

All Endogenous Metabolite Isoforms

Biological Activity

Chemical Information

Publications (10)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Benzo[a]pyrene

Metabolism/Protease Compound Library

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Lung Cancer Compound Library

Tumorigenesis-Related Compound Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Mitochondrial Toxicity Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Tibetan Medicine Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Benzo[a]pyrene

All Endogenous Metabolite Isoforms

Biological Activity

Chemical Information

Publications (10)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Benzo[a]pyrene Related Classifications

HY-107377 Related Classifications